4baseCare secures $6 million Series A funding

New Delhi: 4baseCare has announced a successful $6 million Series A funding round led by Yali Capital, with participation from other investors. The new capital will support the company’s expansion efforts in India and extend its reach into other key markets across Asia and the Middle East.

Yali Capital’s Founding General Partner, Mathew Cyriac expressed, “The genomics landscape in cancer care offers a tremendous opportunity to create impactful businesses while improving millions of lives. As a deep tech-focused fund, we are particularly excited about 4baseCare’s ability to enhance genomic tests with data from underrepresented populations, leading to improved treatment recommendations. 4baseCare has demonstrated impressive growth over the last few years, and we look forward to helping the team build a sustainable and profitable business.”

Hitesh Goswami, CEO and Co-Founder of 4baseCare, emphasized, “4baseCare was founded with an aim to address the critical genomic data gap in cancer care. Our journey from developing TARGT Indiegene to impacting the lives of over 10,000 patients has been a very fulfilling experience. The success of our test and our growth over the years is a result of the exceptional support from our investors and the invaluable insights from our advisory board. This funding will further enable us to enhance our product offerings and advance our mission of making personalized cancer care accessible to millions.”

4baseCare’s genomic tests have already made a notable impact in SouthEast Asia, serving over 10,000 cancer patients. The company’s growth is bolstered by a distinguished Advisory Board, which recently welcomed Francis deSouza, a former CEO of Illumina and a Silicon Valley tech veteran with over 30 years of expertise in genomics and technology.

In the coming months, 4baseCare plans to establish genomics laboratories in the Philippines, Nepal, and Dubai. The company will also focus on advancing its genomics and digital health solutions, with an emphasis on improved data analytics, clinical insights, and data-driven treatment recommendations.